Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if IBIO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
17 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
55 filers reported a long position in IBIO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Affinity Asset Advisors, LLC | $7M | 4M | +29% |
| Cormorant Asset Management, LP | $6.2M | 3.6M | New |
| SILVERARC CAPITAL MANAGEMENT, LLC | $6.2M | 3.5M | +1,457.7% |
| Vestal Point Capital, LP | $4.6M | 2.6M | New |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.7M | 2.1M | +92.8% |
| Frazier Life Sciences Management, L.P. | $3.4M | 2M | Unchanged |
| Ensign Peak Advisors, Inc | $3.2M | 1.8M | New |
| Woodline Partners LP | $3.1M | 1.8M | New |
| MILLENNIUM MANAGEMENT LLC | $2.9M | 1.7M | +6.6% |
| CITADEL ADVISORS LLC | $2.4M | 1.4M | +44.7% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.